PharMerica Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to PharMerica Reports Second Quarter 2015 Results
August 10, 2015 6:59 AM EDT
(Updated - August 10, 2015 9:10 AM EDT)
UBS upgraded PharMerica (NYSE: PMC) from Neutral to Buy with a sum-of-the-parts valuation of $40. Analyst Steven Valiquette is positive on its faster-growing specialty business, reduced litigation overhang, and underappreciated generic pipeline.
"First, we believe the company's faster-growing specialty business which is now could hit $400 mil in revs during '15, a goal PMC mgmt originally set for '16, is now big enough to warrant a 'sum-of-the-parts' valuation vs. simply valuing the... More
August 7, 2015 8:05 AM EDT
Pharmerica (NYSE: PMC) reported Q2 EPS of $0.37, $0.04 better than the analyst estimate of $0.33. Revenue for the quarter came in at $497 million versus the consensus estimate of $491.66 million.
Pharmerica sees FY2015 EPS of $1.55-$1.65, versus the consensus of $1.63. Pharmerica sees FY2015 revenue of $1.95-2.05... More
